CoChat
Sign Up
Cited by 41

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells

Qi, Chen, Wang, Xin, Shen, Zhirong, Chen, She, Yu, Hong, Williams, Noelle, Wang, Gelin·2018·Cell Research
DOI 10.1038/s41422-018-0018-6PMC PMC5951888
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41422-018-0018-6

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 4 references

Research works printed but not linked: 43

  1. Wood, K. W., Cornwell, W. D. & Jackson, J. R. Past and future of the mitotic spindle as an oncology target. Curr. Opin. Pharmacol. 1, 370–377 (2001). · DOI
  2. Bhalla, K. N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 22, 9075–9086 (2003). · DOI
  3. Jackson, J. R., Patrick, D. R., Dar, M. M. & Huang, P. S. Targeted antimitotic therapies: can we improve on tubulin agents? Nat. Rev. Cancer 7, 107–117 (2007). · DOI
  4. Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253–265 (2004). · DOI · Paper page
  5. Paull, K. D., Lin, C. M., Malspeis, L. & Hamel, E. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res. 52, 3892–3900 (1992).
  6. Cruz-Monserrate, Z. et al. Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin. Mol. Pharmacol. 63, 1273–1280 (2003). · DOI
  7. Li, J., Burgett, A. W. G., Esser, L., Amezcua, C. & Harran, P. G. Total synthesis of nominal diazonamides. Part 2: On the true structure and origin of natural isolates. Angew. Chem. Int Ed. Engl. 40, 4770–4773 (2001). · DOI
  8. Wang, G., Shang, L., Burgett, A. W., Harran, P. G. & Wang, X. Diazonamide toxins reveal an unexpected function for ornithine delta-amino transferase in mitotic cell division. Proc. Natl Acad. Sci. USA 104, 2068–2073 (2007). · DOI
  9. Williams, N. S. et al. Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity. Proc. Natl Acad. Sci. USA 104, 2074–2079 (2007). · DOI
  10. Wieczorek, M. et al. The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. Sci. Transl. Med. 8, 365ra159 (2016). · DOI
  11. Tunquist, B. J., Woessner, R. D. & Walker, D. H. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Mol. Cancer Ther. 9, 2046–2056 (2010). · DOI
  12. Sloss, O., Topham, C., Diez, M. & Taylor, S. Mcl-1 dynamics influence mitotic slippage and death in mitosis. Oncotarget 7, 5176–5192 (2016). · DOI
  13. Wertz, I. E. et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471, 110–114 (2011). · DOI
  14. Ham, J. et al. Exploitation of the apoptosis-primed state of MYCN-amplified neuroblastoma to develop a potent and specific targeted therapy combination. Cancer Cell 29, 159–172 (2016). · DOI
  15. Miller, A. V. et al. Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor. PLoS ONE 8, e60685 (2013). · DOI
  16. Colin, D. J., Hain, K. O., Allan, L. A. & Clarke, P. R. Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins. Open Biol. 5, 140156 (2015). · DOI
  17. Rieder, C. L. & Maiato, H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev. Cell 7, 637–651 (2004). · DOI
  18. Weaver, B. A. & Cleveland, D. W. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 8, 7–12 (2005). · DOI
  19. Li, Y. & Benezra, R. Identification of a human mitotic checkpoint gene: hsMAD2. Science 274, 246–248 (1996). · DOI
  20. Jiang, X. & Wang, X. Cytochrome C-mediated apoptosis. Annu Rev. Biochem 73, 87–106 (2004). · DOI
  21. Thornberry, N. A. & Lazebnik, Y. Caspases: enemies within. Science 281, 1312–1316 (1998). · DOI
  22. Petersen, S. L. et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12, 445–456 (2007). · DOI
  23. Wang, G. et al. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat. Chem. Biol. 9, 84–89 (2013). · DOI
  24. Green, D. R. Apoptotic pathways: ten minutes to dead. Cell 121, 671–674 (2005). · DOI
  25. Ashkenazi, A. & Dixit, V. M. Death receptors: signaling and modulation. Science 281, 1305–1308 (1998). · DOI · Paper page
  26. Sakurikar, N., Eichhorn, J. M., Alford, S. E. & Chambers, T. C. Identification of a mitotic death signature in cancer cell lines. Cancer Lett. 343, 232–238 (2014). · DOI
  27. Terrano, D. T., Upreti, M. & Chambers, T. C. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol. Cell Biol. 30, 640–656 (2010). · DOI
  28. Chinnaiyan, A. M. et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274, 990–992 (1996). · DOI
  29. Screaton, G. R. et al. LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc. Natl Acad. Sci. USA 94, 4615–4619 (1997). · DOI
  30. Nakayama, M. et al. Multiple pathways of TWEAK-induced cell death. J. Immunol. 168, 734–743 (2002). · DOI
  31. Tao, W. et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 8, 49–59 (2005). · DOI
  32. Migone, T. S. et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16, 479–492 (2002). · DOI
  33. Meylan, F. et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 29, 79–89 (2008). · DOI
  34. Marsters, S. A. et al. Identification of a ligand for the death-domain-containing receptor Apo3. Curr. Biol. 8, 525–528 (1998). · DOI
  35. Kaptein, A. et al. Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3). FEBS Lett. 485, 135–141 (2000). · DOI
  36. Wiley, S. R. et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15, 837–846 (2001). · DOI
  37. Chin, L., Andersen, J. N. & Futreal, P. A. Cancer genomics: from discovery science to personalized medicine. Nat. Med 17, 297–303 (2011). · DOI
  38. Neale, G. et al. Molecular characterization of the pediatric preclinical testing panel. Clin. Cancer Res 14, 4572–4583 (2008). · DOI
  39. Schaefer, K. L. et al. Microarray analysis of Ewing’s sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur. J. Cancer 44, 699–709 (2008). · DOI
  40. Inuzuka, H. et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471, 104–109 (2011). · DOI
  41. Kueh, H. Y., Zhu, Y. & Shi, J. A simplified Bcl-2 network model reveals quantitative determinants of cell-to-cell variation in sensitivity to anti-mitotic chemotherapeutics. Sci. Rep. 6, 36585 (2016). · DOI
  42. Ashkenazi, A. & Dixit, V. M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11, 255–260 (1999). · DOI
  43. Gascoigne, K. E. & Taylor, S. S. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14, 111–122 (2008). · DOI · Paper page

Cited by

Sorted by citations

See all 41

Metadata

Authors
Qi, C., Wang, X., Shen, Z., Chen, S., Yu, H., Williams, N., & Wang, G.
Venue
Cell Research
Publisher
Springer Science and Business Media LLC
Published
2018-03-01
Volume
28
Issue
5
Pages
544-555
ISSN
  • 1001-0602
  • 1748-7838
DOI
10.1038/s41422-018-0018-6
PMC
PMC5951888
Cited by
41
References
4
Language
en
Licence
creativecommons.org/licenses/by/4.0 (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review